Sanger sequencing primer combination for Omicron typing and detection kit
By designing the Sanger sequencing primer combination and kit, the rapid and accurate classification of Omicron strains is achieved, and the problems of high detection costs and insufficient sensitivity in the prior art are solved, the reagent and labor costs are reduced, and it is suitable for large-scale testing.
Patent Information
- Application Number
- CN202310535739.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-11
- Publication Date
- 2024-11-12
AI Technical Summary
The existing technology has problems such as high cost, high labor cost, insufficient sensitivity and false positives in the Omicron typing detection of the new coronavirus. Especially, second-generation sequencing and NGS technology are difficult to popularize in large-scale testing, Sanger sequencing only uses It is not used for classification when judging positive.
A Sanger sequencing primer combination and kit was designed to realize the 3-tube merged amplification reaction by adjusting the primer ratio and PCR system, covering 42 amino acid sites in the N-protein region, S-protein region, M-protein region and ORF region. Reduce reagent and labor costs, and combine Sanger sequencing to perform typing detection of Omicron strains.
It has achieved rapid and accurate classification of Omicron strains, reduced testing costs, and is suitable for clinical accurate diagnosis and treatment and scientific research. The cost is about 1/4 of the traditional methods and is suitable for large-scale testing.
Smart Images

Figure SMS_1 
Figure SMS_3 
Figure SMS_4
Abstract
Description
Technical Field
[0001] The present application relates to the field of bioinformatics, and specifically to a Sanger sequencing primer set and a kit, and more specifically to a Sanger sequencing primer combination and a detection kit for Omicron typing. The present application also provides a method for Omicron strain typing. Background Art
[0002] The new coronavirus (SARS-CoV-2) is a single-stranded RNA virus of the Coronaviridae family. The viral genome is about 30kb in length and consists of genes encoding a variety of non-structural, structural and accessory proteins. Since the new coronavirus is an RNA virus, it is more likely to mutate during replication than DNA. Taking Omicron as an example, it includes more than 700 subtypes. This mutation may lead to changes in protein function and its viral transmission and pathogenesis mechanism, and thus have great differences in clinical phenotype, treatment and prognosis. Therefore, how to efficiently and quickly perform typing is of great significance to clinical and scientific research.
[0003] At present, there are already a large number of test kits designed specifically for the new coronavirus on the market. These test kits combined with second-generation sequencing can also obtain high-quality new coronavirus typing results. However, this method requires special experimental extraction, library construction, sequencing, analysis and other steps, which consumes a lot of manpower and material resources.
[0004] The mNGS technology of the second-generation sequencing has high detection costs, and requires more than 3,000 reads for each strain to identify the typing, which is not sensitive enough. Although the tNGS technology of NGS can identify the typing, it is difficult to bear large-scale testing due to the high sample input requirements and high detection costs of NGS technology, and is not suitable for large-scale clinical popularization. qRT-PCR is a commonly used technology for detecting the new coronavirus. It uses dual-target specific detection. This technology has high specificity, high sensitivity, low detection cost, and short detection time. It can monitor the amplification product in real time, but this technology can only determine whether the virus exists through fluorescent signals, and cannot determine the virus typing. It is prone to cross contamination and false positives. Sanger sequencing technology is one of the earliest technologies that can accurately determine DNA sequences, but there are many mutation sites in Omicron, and typing requires the design of multiple primers, multiple amplifications and sequencing, resulting in the loss of cost advantages relative to NGS technology. Existing technologies only use it to determine whether the subject is positive, and are not used for Omicron typing. Summary of the invention
[0005] The present application proposes a primer combination, which consists of primers represented by Seq ID No: 1-14.
[0006] Preferably, in the primer combination, each primer represented by Seq ID No: 1-14 has the same amount ratio of the substance.
[0007] The present application further provides a kit comprising the primer combination according to claim 1 or 2.
[0008] Preferably, the primers in the kit form three sets of primer compositions, the first primer composition consisting of primers of Seq ID No: 1-6; the second primer composition consisting of primers of Seq ID No: 7-10; and the third primer composition consisting of primers of Seq ID No: 10-14.
[0009] The kit also includes a liquefaction reagent, an extraction reagent, a reverse transcription reagent, an amplification reagent and a Sanger sequencing reagent. The various reagents can be directly used from various commercially available kits or prepared by oneself.
[0010] The present application also provides a method for typing the Omicron strain, using the primer combination or kit described in the present application to perform PCR amplification and Sanger sequencing on the single-stranded cDNA template, comparing the sequencing result with the sequence of the Omicron strain, and determining the typing of the Omicron strain corresponding to the cDNA template.
[0011] The Omicron strain is selected from: BA.5.2, BF.7, BA.5.2.1, BA.5 / BA.5.1, BA.2.2.1, BA.5.9, BN.1.3 / BN.1.2 / BN.1.3.1, BQ.1 , BA.5.2.16, BA.5.2.24, XBB.1, BQ.1.1, CH.1.1, BA.2.3.20, BA.5.2.6, BN.1.5, BF.5, BQ.1.1.18 and BE.1.1 subtypes.
[0012] Among the above strains, the use of the primer combination and kit of the present application can only determine whether the virus is BA.5 / BA.5.1, but cannot distinguish which of the two subtypes it is; similarly, the use of the primer combination and kit of the present application can only determine whether the virus is BN.1.3 / BN.1.2 / BN.1.3.1, but cannot distinguish which of the three subtypes it is.
[0013] Preferably, the Sanger sequencing is performed by 3-tube amplification, and the primers put into each tube are primers of Seq ID No: 1-6, primers of Seq ID No: 7-10 and primers of Seq ID No: 10-14.
[0014] As another preference, when performing the Sanger sequencing, only the F single end is determined for Seq ID Nos: 1-2, 5-6 and 13-14, only the R single end is determined for Seq ID Nos: 3-4, and FR double ends are determined for Seq ID Nos: 7-12.
[0015] The present application also provides the use of the primer combination or kit in Omicron strain typing.
[0016] The "primer combination" referred to in this application is only a general term for multiple primers, and does not mean that they have been mixed during the manufacturing, storage, and transportation process; the "primer composition" referred to in this application refers to a composition formed by mixing multiple primers, which may contain various solvents or no solvent. The numbers in the so-called "first primer composition", "second primer composition", and "third primer composition" are only used for distinction and do not represent any limitation on the characteristics.
[0017] The "first container", "second container" and "third container" referred to in this application indicate that the spaces inside them are isolated from each other, and do not mean that the three containers must be physically independent of each other. For example, a container with three independent sealed spaces can be provided, which are used to hold the first, second and third primer combinations respectively, and the container still meets the description of the "first container", "second container" and "third container" in this application.
[0018] This application is mainly aimed at using Sanger sequencing to detect common typing of the new coronavirus, among which 7 pairs of primers are designed for the 22 common subtypes of the currently popular "Omicron". Through the design of primers and the adjustment of their combination, a 3-tube combined amplification reaction is realized to complete the amplification of the 7 pairs of primers, covering the nsp specific region of the N protein region, S protein region, M protein region and ORF region, with a total of 42 amino acid sites. This application realizes combined amplification by combining primers by adjusting the primer ratio and PCR system, and designs single-end or double-end sanger sequencing according to the size of the typing region, while ensuring the accuracy of the detection, greatly reducing the reagent cost and labor cost. According to the current reagent price, considering the depreciation of the instrument and the labor cost, the cost of using the mNGS method is about 500 yuan, the cost of the tNGS method is about 280 yuan, and the method of this application only costs 140 yuan.
[0019] This application can empower clinical precision diagnosis and treatment, scientific research exploration, and epidemiological investigation. At the same time, based on the variation characteristics of the viral metagenome, it can analyze the unique variation sites, variation patterns, and transmission patterns of viral evolution, providing a theoretical basis for tracing the virus and determining the virus transmission chain. DETAILED DESCRIPTION
[0020] In order to better understand the present application, the technical solution of the present application will be described in more detail with reference to the accompanying drawings. It should be understood that these detailed descriptions are only descriptions of exemplary embodiments of the present application and are not intended to limit the scope of the present application in any way. Throughout the specification, the same reference numerals refer to the same elements. The expression "and / or" includes any combination or all combinations of one or more items in the associated listed items.
[0021] It should be noted that in this specification, the expressions "first", "second", "third", etc. are only used to distinguish one feature from another feature, and do not represent any limitation on the features. Therefore, without departing from the teachings of this application, for example, the first XXX discussed below may also be referred to as the second XXX, the Ath XXX, the (3)th XXX, etc.
[0022] In the accompanying drawings, the size, proportions and shapes of the figures have been slightly adjusted for ease of illustration. The drawings are for illustration only and are not drawn strictly to scale. As used herein, the terms "substantially," "approximately," and similar terms are used as terms of approximation, not degree, and are intended to account for the inherent deviations in measurements or calculations that would be recognized by one of ordinary skill in the art.
[0023] It should also be understood that expressions such as "including", "comprising", "having", "containing" and / or "comprising" are open rather than closed expressions in this specification, which indicate the presence of the stated features, elements and / or components, but do not exclude the presence of one or more other features, elements, components and / or combinations thereof. In addition, when expressions such as "at least one of..." appear after a list of listed features, they modify the entire list of features rather than just a single feature in the list. In addition, when describing embodiments of the present application, "may" is used to mean "one or more embodiments of the present application". And, the wording "exemplary" is intended to refer to an example or illustration.
[0024] Unless otherwise specified, all words (including engineering terms and scientific and technological terms) used in this article have the same meaning as those commonly understood by ordinary technicians in the field to which this application belongs. It should also be understood that, unless clearly stated in this application, words defined in common dictionaries should be interpreted as having the same meaning as their meaning in the context of the relevant technology, and should not be interpreted in an idealized or overly formal sense.
[0025] It should be noted that, in the absence of conflict, the features in the embodiments and examples of the present application can be combined with each other. In addition, unless explicitly limited or contradictory to the context, the specific steps included in the method described in the present application are not necessarily limited to the order described, but can be performed in any order or in parallel. The present application will be described in detail below with reference to the accompanying drawings and in combination with the embodiments.
[0026] Example 1, primer design, grouping and kit design.
[0027] Seven pairs of primers were designed for the detection sites of common subtypes of Omicron, and the sequences were Seq ID No: 1-14. The above primer combinations can be divided into three tubes, namely the first primer combination, the second primer combination, and the third primer combination. The relevant information is shown in Table 1.
[0028] Table 1, Primer information and grouping.
[0029]
[0030] The above primers can determine the virus subtype by detecting specific detection sites, see Table 2 and Table 3 for details. Take a BA.5.2-type positive sample as an example: after primer amplification, if Nsp1-1-1, M-1-1, and N-1-1 detect that the sample has mutations in protein No. 135 of the Nsp1 gene, protein No. 3 of the M gene, and protein No. 19 of the N gene, then the sample can be considered to be a BA.5.2-type positive sample.
[0031] Table 2, detected mutation sites and virus lineages (subtypes).
[0032]
[0033]
[0034] Note: The lineage corresponding to sequence number 4 in the table is BA.5 / BA.5.1, indicating that the structures of the two subtypes are too similar. The primers of this application can only determine whether the virus is at least one of the two subtypes, but cannot confirm which of the two subtypes it is. The lineage corresponding to sequence number 7, BN.1.3 / BN.1.2 / BN.1.3.1, also belongs to this situation where it cannot be subdivided.
[0035] Table 3, detection sites corresponding to each primer pair.
[0036]
[0037]
[0038] This embodiment also gives an example of a kit, which includes three containers, each containing a first primer composition, a second primer composition, and a third primer composition; it may also include other reagents required for Sanger sequencing; the enzyme may be in dry powder form or solution form.
[0039] Other reagents required for the Sanger sequencing may be the reagents listed in Example 2 of the present application, or various commercially available kits may be used, for example: liquefaction reagent: trypsin dry powder (Shanghai Bioengineering Co., Ltd.) A600626; extraction kit: Tiangen viral RNA extraction kit (DP315-R) 50 people / box; reverse transcription kit: Novagen HiScript III 1st Strand cDNA Synthesis Kit (+gDNA wiper) R312-01; amplification kit: Novagen Phanta Max Super-Fidelity DNA Polymerase P505-d1; sequencing kit: 125mM EDTA pH=8.0, 3M NaAc pH=5.2, anhydrous ethanol, Terminator v3.1CycleSequencing Kit Applied Biosystems, Cat.No.:4337457, Formamide, genetic analysis grade, 25 mL (Applied Biosystems, catalog number: 4311320), POP-7 TM Polymer for 3500 / 3500xlGenetic Analyser, 960 samples Applied Biosystems, Cat No.: 4393708, 2.4.21Cathode Buffer Container (CBC) 3500 Series Applied Biosystems, Cat No.: 4408256, Anode Buffer Container (ABC) 3500 Series Applied Biosystems, Cat No.: 4393927. The above are all exemplary, and those skilled in the art can configure other liquefaction reagents, extraction reagents, reverse transcription reagents, amplification reagents, sequencing reagents, etc. that have the same functions as needed.
[0040] Through the above grouping and merging, the number of reactions required for PCR amplification is reduced to 3, the demand for the total amount of samples is reduced, and the cost is reduced. Further merging or changing the merging method will cause inconsistent amplification efficiency of multiple primers in one tube. The current grouping is the optimal solution found by the inventor.
[0041] As a variation of the above-mentioned kit, the six enzymes in the first primer composition can be packaged in two, three, four, five or six containers, and this packaging does not affect the mixing during actual use; similarly, the second primer composition and the third primer composition can also be packaged in multiple containers.
[0042] Example 2, Omicron strain typing.
[0043] (A) Sample acquisition and pre-processing.
[0044] The experimental materials of this embodiment are respiratory samples and throat swab samples from 10 viral infection patients admitted to a hospital and confirmed by pathology, and RNA is extracted from the materials of the same patient. If the sample state is viscous, the sample is pre-treated, or liquefied: take 500 μL of viscous sample, add 1.5 times the volume (750 μL) of liquefied working solution, incubate at 37 ° C for 15-30 minutes, and shake the bottom of the sample collection tube once every 5 minutes. When the viscous sample becomes a non-blocky viscous substance and no floccules, the sample becomes clear and can flow in a liquid state, and the reaction is stopped immediately. If the liquefaction is incomplete, the liquefaction time is appropriately delayed for 5 minutes. After the liquefaction is completed, centrifuge at 12000rpm for 1 minute and collect 1mL of supernatant.
[0045] (ii) Nucleic acid extraction
[0046] Centrifugation: Take 1 ml of sample (for samples that need to be liquefied, take 1 mL of the supernatant obtained by centrifugation after liquefaction), centrifuge at 6000×g for 10 min (4°C), filter through a 0.22μm filter membrane, and take 750μL of the filtrate into a new 2mL centrifuge tube for later use.
[0047] Enzyme digestion: If the sample is sputum, add 1 / 20 of the volume of DNase and 1 / 10 of the volume of DNase Buffer to the filtrate; if the sample is bronchoalveolar lavage fluid or swab sample, add 1 / 10 of the volume of DNase and 1 / 5 of the volume of DNase Buffer to the filtrate.
[0048] Incubation: 37°C, 30 min; DNase inactivation: 80°C, 2 min; add 750 μL RL-Carrier RNA mixed solution (a mixture of lysis solution RL and Carrier RNA working solution, the preparation method is shown in Table 4, invert to mix, do not shake to mix, which is easy to produce bubbles) into a clean 2 mL centrifuge tube.
[0049] Table 4: Preparation of RL-Carrier RNA mixture.
[0050]
[0051]
[0052] Add 750 μL of sample to the centrifuge tube, vortex for 15 seconds to mix; incubate at room temperature for 15 minutes; briefly centrifuge to collect the liquid attached to the tube wall and the tube cover; add 500 μL of anhydrous ethanol, cover the tube and vortex for 15 seconds. Briefly centrifuge to collect the liquid attached to the tube wall and the tube cover; transfer the liquid to the RNase-Free adsorption column CR2 (the adsorption column is placed in the collection tube), cover the tube, centrifuge at 6000×g for 1 minute, discard the waste liquid, and put the adsorption column back into the collection tube.
[0053] Carefully open the cover of the adsorption column, add 500 μL of solution GD (please check whether anhydrous ethanol has been added before use), cover the tube, centrifuge at 6000×g for 1 min, discard the waste liquid, and put the adsorption column back into the collection tube.
[0054] Carefully open the cover of the adsorption column, add 500 μL of solution RW (please check whether anhydrous ethanol has been added before use), cover the tube, centrifuge at 6000×g for 1 min, discard the waste liquid, put the adsorption column back into the collection tube; repeat the operation.
[0055] Place the adsorption column back into the collection tube, centrifuge the empty tube at 13,400×g for 3 min, and discard the waste liquid. Place the adsorption column into a new 1.5 mL collection tube, open the cover of the adsorption column, and leave it at room temperature for 3 min to allow the adsorption film to completely dry.
[0056] Add 25uL NF water in the middle of the membrane, cover the lid, leave at room temperature for 5 minutes, centrifuge at 6000×g (8000rpm) for 1 minute; repeat this operation.
[0057] After checking the sample number, the adsorption column was discarded, and the extracted RNA sample was subjected to RNA Qubit concentration determination. The RNA was stored at -20°C for a short term and -80°C for a long term.
[0058] (III) Obtaining template cDNA.
[0059] Prepare the first-strand cDNA synthesis reaction system in a sterilized PCR tube:
[0060] Table 5 RNA denaturation reaction system.
[0061]
[0062] Vortex to mix, remove bubbles in the reaction system, centrifuge briefly for 2 seconds, and then perform the following denaturation procedure:
[0063] Table 6 RNA denaturation reaction PCR program.
[0064]
[0065] After the reaction is completed, take out the PCR tube after RNA denaturation reaction from the PCR instrument, centrifuge it instantly, and prepare the genomic DNA removal reaction system in the PCR tube:
[0066] Table 7 Genomic DNA removal reaction system.
[0067]
[0068] Vortex to mix, remove bubbles in the reaction system, centrifuge briefly, and then perform the following reverse transcription procedure:
[0069] Table 8 Genomic DNA removal PCR program.
[0070]
[0071] After the reaction is completed, take out the genomic DNA from the PCR instrument, remove the PCR tube after the reaction, centrifuge it instantly, and configure the cDNA first-chain synthesis reaction system in the PCR tube:
[0072] Table 9 cDNA first-strand synthesis reaction system.
[0073]
[0074]
[0075] Vortex to mix, remove bubbles in the reaction system, centrifuge briefly, and then perform the following reverse transcription procedure:
[0076] Table 10 PCR program for cDNA first strand synthesis reaction.
[0077]
[0078] After the PCR program was completed, the reaction product was taken out and centrifuged for 2 seconds to obtain a single-stranded cDNA template.
[0079] (IV) Performing a round of PCR amplification reaction using the primer combination of the present application
[0080] (1) PCR amplification reaction using single-stranded cDNA as template
[0081] The following reaction system was prepared in a sterilized PCR tube, divided into 3 tubes, and the first primer combination of Seq ID No: 1-6, the second primer combination of Seq ID No: 7-10 and the third primer combination of Seq ID No: 11-14 were added respectively. The upstream primer and downstream primer in Table 10 refer to the amount of each upstream primer or downstream primer:
[0082] Table 11 cDNA template first round PCR amplification reaction system
[0083]
[0084]
[0085] Vortex the prepared reaction system thoroughly, centrifuge it instantaneously, and perform the following PCR reaction procedure:
[0086] Table 12 cDNA PCR amplification program
[0087]
[0088] After the PCR program was completed, the reaction product was taken out, centrifuged for 2 seconds, and the concentration of the amplified product was measured using Qubit dsDNA HS Assay.
[0089] Sanger sequencing
[0090] After the amplified products of the 10 samples were purified, the settings were made according to the instrument manual of the 3500xl genetic analyzer and the program was started. After the machine was turned off, the Sanger sequencing result sequences were obtained in turn, and the gene sequences of each sample were compared and analyzed.
[0091] Test results
[0092] After comparing the results of Sanger sequencing of the amplified products of the 10 samples with the results of second-generation sequencing of the same samples, it is believed that the results of Sanger sequencing are consistent with the results of second-generation sequencing. It should be noted that most of the samples collected in Guangdong during the trial of this application were BA.5.2.16 and BA.5.2.6 subtypes, but this does not mean that the primers and kits of this application can only be used to detect the above subtypes. Based on the sites covered by the primers of this application, technicians in this field can infer the strains that can be typed.
[0093] Table 13 Mutation detection results
[0094]
[0095]
[0096] Example 3, improvement of sequencing method.
[0097] As a preference for the technical solution of Example 2, for primers longer than 1000 bp, double-end sequencing is used. For primers with a coverage of less than 1000 bp, single-end sequencing is used. While ensuring full coverage of the typing sites, the reagent cost and time cost brought about by the adjustment from double-end to single-end are reduced.
[0098] Table 14 Comparison of the effects of double-end sequencing and the optimized method of Example 3
[0099]
[0100]
[0101] The above description is only an implementation method of the present application and an explanation of the technical principles used. Those skilled in the art should understand that the scope of protection involved in the present application is not limited to the technical solution formed by a specific combination of the above technical features, but should also cover other technical solutions formed by any combination of the above technical features or their equivalent features without departing from the technical concept. For example, the above features are replaced with (but not limited to) technical features with similar functions disclosed in this application.
Claims
1. A primer combination, characterized in that: It consists of primers represented by Seq ID No: 1-14.
2. The primer combination according to claim 1, characterized in that In the primer combination, each primer represented by Seq ID No: 1-14 has the same amount ratio of the substance.
3. A kit, characterized in that: A primer combination according to claim 1 or 2.
4. The kit according to claim 3, characterized in that The primers form three sets of primer combinations, A first primer combination, consisting of primers of Seq ID No: 1-6; a second primer combination consisting of primers of Seq ID Nos: 7-10; The third primer combination consists of primers of Seq ID Nos: 10-14.
5. The kit according to claim 3 or 4, characterized in that The kit also comprises a liquefaction reagent, an extraction reagent, a reverse transcription reagent, an amplification reagent and a Sanger sequencing reagent.
6. A method for typing Omicron strains, characterized in that: Use the primer combination described in claim 1 or 2, or the kit described in any one of claims 3-5 to perform PCR amplification and Sanger sequencing on the single-stranded cDNA template, compare the sequencing result with the sequence of the Omicron strain, and determine the typing of the Omicron strain corresponding to the cDNA template.
7. The method according to claim 6, characterized in that The Omicron strain is selected from: BA.5.2, BF.7, BA.5.2.1, BA.5 / BA.5.1, BA.2.2.1, BA.5.9, BN.1.3 / BN.1.2 / BN.1.3.1, BQ. 1, BA.5.2.16, BA.5.2.24, XBB.1, BQ.1.1, CH.1.1, BA.2.3.20, BA.5.2.6, BN.1.5, BF.5, BQ.1.1.18 and BE.1.
1.
8. The method according to claim 7, characterized in that The Sanger sequencing was performed by 3-tube amplification, and the primers put into each tube were primers of Seq ID No: 1-6, primers of Seq ID No: 7-10 and primers of Seq ID No: 10-14.
9. The method according to claim 6, characterized in that When performing the Sanger sequencing, only the F single end was determined for Seq ID Nos: 1-2, 5-6, and 13-14, only the R single end was determined for Seq ID Nos: 3-4, and FR double ends were determined for Seq ID Nos: 7-12.
10. Use of the primer combination according to claim 1 or 2 or the kit according to any one of claims 3 to 5 in typing of Omicron strains.
